Zobrazeno 1 - 8
of 8
pro vyhledávání: '"European Research Initiative on CLL (ERIC)"'
Autor:
Lesley-Ann Sutton, Viktor Ljungström, Anna Enjuanes, Diego Cortese, Aron Skaftason, Eugen Tausch, Katerina Stano Kozubik, Ferran Nadeu, Marine Armand, Jikta Malcikova, Tatjana Pandzic, Jade Forster, Zadie Davis, David Oscier, Davide Rossi, Paolo Ghia, Jonathan C. Strefford, Sarka Pospisilova, Stephan Stilgenbauer, Frederic Davi, Elias Campo, Kostas Stamatopoulos, Richard Rosenquist, European Research Initiative on CLL (ERIC)
Publikováno v:
Haematologica, Vol 106, Iss 3 (2020)
Next-generation sequencing (NGS) has transitioned from research to clinical routine, yet the comparability of different technologies for mutation profiling remains an open question. We performed a European multicenter (n=6) evaluation of three amplic
Externí odkaz:
https://doaj.org/article/715f66afe1e34e4ea30982ecf017a715
Autor:
Dreger, Peter, Ghia, Paolo, Schetelig, Johannes, van Gelder, Michel, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Robak, Tadeusz, Stilgenbauer, Stephan, Montserrat, Emili, on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Publikováno v:
In Blood 30 August 2018 132(9):892-902
Autor:
Cuneo, Antonio, Follows, George, Rigolin, Gian Matteo, Piciocchi, Alfonso, Tedeschi, Alessandra, Trentin, Livio, Perez, Angeles Medina, Coscia, Marta, Laurenti, Luca, Musuraca, Gerardo, Farina, Lucia, Delgado, Alfredo Rivas, Orlandi, Ester Maria, Galieni, Piero, Mauro, Francesca Romana, Visco, Carlo, Amendola, Angela, Billio, Atto, Marasca, Roberto, Chiarenza, Annalisa, Meneghini, Vittorio, Ilariucci, Fiorella, Marchetti, Monia, Molica, Stefano, Re, Francesca, Gaidano, Gianluca, Gonzalez, Marcos, Forconi, Francesco, Ciolli, Stefania, Cortelezzi, Agostino, Montillo, Marco, Smolej, Lukas, Schuh, Anna, Eyre, Toby A, Kennedy, Ben, Bowles, Kris M, Vignetti, Marco, de la Serna, Javier, Moreno, Carol, Foà, Robin, Ghia, Paolo, GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d24b88f44e2262e2f6fabc65579c98fe
https://hdl.handle.net/10668/12372
https://hdl.handle.net/10668/12372
Autor:
Herishanu Y; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.; Department of Hematology, and., Avivi I; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.; Department of Hematology, and., Levi S; Department of Hematology, and., Shefer G; Department of Endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Bronstein Y; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.; Department of Hematology, and., Moshiashvili MM; Department of Endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Ziv T; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel., Scarfò L; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; and.; Faculty of Medicine, Università Vita-Salute San Raffaele, Milan, Italy., Perry C; Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.; Department of Hematology, and., Ghia P; European Research Initiative on CLL (ERIC), Barcelona, Spain.; Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; and.; Faculty of Medicine, Università Vita-Salute San Raffaele, Milan, Italy.
Publikováno v:
Blood advances [Blood Adv] 2022 Jan 11; Vol. 6 (1), pp. 148-151.
Autor:
Herishanu Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Hematology and., Avivi I; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Hematology and., Aharon A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Hematology and., Shefer G; Department of Endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Levi S; Department of Hematology and., Bronstein Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Hematology and., Morales M; Department of Endocrinology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Ziv T; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Shorer Arbel Y; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Scarfò L; Division of Experimental Oncology, Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy.; European Research Initiative on CLL (ERIC), Barcelona, Spain; and., Joffe E; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center-Weill Cornell College of Medicine, New York, NY., Perry C; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Hematology and., Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele, IRCCS Ospedale San Raffaele, Milan, Italy.; European Research Initiative on CLL (ERIC), Barcelona, Spain; and.
Publikováno v:
Blood [Blood] 2021 Jun 10; Vol. 137 (23), pp. 3165-3173.
Autor:
Sutton LA; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, Ljungström V; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Enjuanes A; Institut d’Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain and Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain, Cortese D; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, Skaftason A; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, Tausch E; Department of Internal Medicine III, Ulm University,Ulm, Germany, Stano Kozubik K; Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Nadeu F; Institut d’Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain and Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain, Armand M; AP-HP, Hopital Pitie-Salpetriere, Department of Hematology, Sorbonne Université, Paris, France, Malcikova J; Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Pandzic T; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, Forster J; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK;, Davis Z; Department of Hematology, Royal Bournemouth Hospital, Bournemouth, UK, Oscier D; Department of Hematology, Royal Bournemouth Hospital, Bournemouth, UK, Rossi D; Hematology Department, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland, Ghia P; Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS San Raffaele Scientific Institute, Milan, Italy, Strefford JC; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK;, Pospisilova S; Center of Molecular Medicine, CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Stilgenbauer S; Department of Internal Medicine III, Ulm University,Ulm, Germany, Davi F; AP-HP, Hopital Pitie-Salpetriere, Department of Hematology, Sorbonne Université, Paris, France, Campo E; Institut d’Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain and Hospital Clínic of Barcelona, Universitat de Barcelona, Barcelona, Spain, Stamatopoulos K; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Institute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greec, Rosenquist R; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Clinical Genetics, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden, On Behalf Of The European Research Initiative On Cll Eric
Publikováno v:
Haematologica [Haematologica] 2021 Mar 01; Vol. 106 (3), pp. 682-691. Date of Electronic Publication: 2021 Mar 01.
Autor:
Eichhorst B; Department I Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, University of Cologne, Germany., Ghia P; Strategic Research Program on CLL, Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.; European Research Initiative on CLL (ERIC)/EHA Scientific Working Group on CLL, The Hague, The Netherlands.
Publikováno v:
HemaSphere [Hemasphere] 2020 Dec 29; Vol. 5 (1), pp. e520. Date of Electronic Publication: 2020 Dec 29 (Print Publication: 2021).
Autor:
Dreger P; Department of Medicine V, University of Heidelberg, Heidelberg, Germany.; European Society for Blood and Marrow Transplantation (EBMT), Paris, France., Montserrat E; Department of Hematology, Hospital Clínic, University of Barcelona, Barcelona, Spain.; European Research Initiative on CLL (ERIC), Barcelona, Spain.
Publikováno v:
Bone marrow transplantation [Bone Marrow Transplant] 2016 Jun; Vol. 51 (6), pp. 765-6. Date of Electronic Publication: 2016 Feb 29.